CN1222536C - 肝细胞癌的预防及治疗 - Google Patents

肝细胞癌的预防及治疗 Download PDF

Info

Publication number
CN1222536C
CN1222536C CNB988052288A CN98805228A CN1222536C CN 1222536 C CN1222536 C CN 1222536C CN B988052288 A CNB988052288 A CN B988052288A CN 98805228 A CN98805228 A CN 98805228A CN 1222536 C CN1222536 C CN 1222536C
Authority
CN
China
Prior art keywords
leu
glu
cells
ala
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988052288A
Other languages
English (en)
Chinese (zh)
Other versions
CN1259139A (zh
Inventor
J·S·艾克挪茅
L·H·巴特菲尔德
A·李巴斯布鲁格拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN1259139A publication Critical patent/CN1259139A/zh
Application granted granted Critical
Publication of CN1222536C publication Critical patent/CN1222536C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB988052288A 1997-02-13 1998-02-13 肝细胞癌的预防及治疗 Expired - Lifetime CN1222536C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3837597P 1997-02-13 1997-02-13
US60/038,375 1997-02-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2005100915162A Division CN1739791A (zh) 1997-02-13 1998-02-13 肝细胞癌的预防及治疗

Publications (2)

Publication Number Publication Date
CN1259139A CN1259139A (zh) 2000-07-05
CN1222536C true CN1222536C (zh) 2005-10-12

Family

ID=21899585

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988052288A Expired - Lifetime CN1222536C (zh) 1997-02-13 1998-02-13 肝细胞癌的预防及治疗
CNA2005100915162A Pending CN1739791A (zh) 1997-02-13 1998-02-13 肝细胞癌的预防及治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005100915162A Pending CN1739791A (zh) 1997-02-13 1998-02-13 肝细胞癌的预防及治疗

Country Status (8)

Country Link
US (1) US20020031520A1 (OSRAM)
EP (1) EP0979239B1 (OSRAM)
JP (3) JP3816959B2 (OSRAM)
KR (1) KR100460583B1 (OSRAM)
CN (2) CN1222536C (OSRAM)
AU (1) AU6435398A (OSRAM)
DE (1) DE69836209D1 (OSRAM)
WO (1) WO1998035981A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058922A2 (en) * 2000-02-10 2001-08-16 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
KR100900742B1 (ko) * 2007-05-17 2009-06-08 크레아젠 주식회사 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법
AU2010309438A1 (en) * 2009-10-22 2012-06-07 Ricardo J. Moro Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof
US10048271B2 (en) 2012-12-11 2018-08-14 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
WO2016161390A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
CN105126074A (zh) * 2015-09-30 2015-12-09 中国药科大学 多肽afp12在制备抗肿瘤药物中的应用
CN105524884A (zh) * 2016-02-29 2016-04-27 时宏珍 Hla-a0201限制性抗afp抗原特异性ctl的制备方法
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1996022787A1 (en) * 1995-01-24 1996-08-01 Murgita Robert A Recombinant human alpha-fetoprotein and uses thereof

Also Published As

Publication number Publication date
WO1998035981A1 (en) 1998-08-20
JP2006188528A (ja) 2006-07-20
JP2001515347A (ja) 2001-09-18
DE69836209D1 (de) 2006-11-30
CN1259139A (zh) 2000-07-05
EP0979239B1 (en) 2006-10-18
US20020031520A1 (en) 2002-03-14
JP3816959B2 (ja) 2006-08-30
JP2010222379A (ja) 2010-10-07
AU6435398A (en) 1998-09-08
CN1739791A (zh) 2006-03-01
EP0979239A4 (en) 2002-09-18
KR20000071226A (ko) 2000-11-25
EP0979239A1 (en) 2000-02-16
KR100460583B1 (ko) 2004-12-08

Similar Documents

Publication Publication Date Title
CN1178956C (zh) 基于癌抑制基因wt1的产物的癌抗原
CN1739791A (zh) 肝细胞癌的预防及治疗
CN1175954A (zh) 由hla分子提呈的分离的九肽及其应用
CN1520311A (zh) 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
CN100347191C (zh) 新mhcⅱ相关肽
CN1203177C (zh) 肿瘤抗原蛋白质及其基因和肿瘤抗原肽
CN1240834C (zh) Ly6h基因
CN1452634A (zh) Hla结合肽及其用途
CN1209876A (zh) 分离的酪氨酸酶衍生肽及其应用
CN1169966C (zh) 酪氨酸酶衍生的分离肽及其应用
CN1176647A (zh) 编码gage肿瘤排斥抗原的分离的截短的核酸分子
CN1218512A (zh) 用于人类肿瘤基因治疗的重组腺病毒载体
CN1264980C (zh) 新型肿瘤抗原蛋白sart－3及其肿瘤抗原肽
CN1255427C (zh) 用于治疗肝细胞癌的方法和组合物
CN1244595C (zh) 一种肿瘤抑制蛋白及其应用
CN1948333A (zh) 一种新的hPEBP4蛋白来源的HLA－A2限制性表位多肽及其应用
CN1262562C (zh) 来源于sart－1的hla－a2限制性肿瘤抗原肽
CN1119169C (zh) 由hla－b44分子提呈的肿瘤排斥抗原及其应用
CN1289524C (zh) 一种人端粒酶活性抑制蛋白及其应用
CN1212398C (zh) 新型ifn受体1结合蛋白质,编码它们的dna,以及调节细胞对干扰素的反应的方法
CN1548455A (zh) 一种肿瘤抗原蛋白质和肿瘤抗原肽
CN1948342A (zh) 一种新的候选癌基因hRabJ来源的HLA－A2限制性表位多肽及其应用
CN1869064A (zh) 一种肿瘤抗原蛋白质和肿瘤抗原肽
CN100341892C (zh) 一种识别反应性星型胶质细胞的标记分子及其应用
HK1001404B (en) Isolated, tyrosinase derived peptides and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20051012